AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Dividend Announcement
• AbbVie announced a quarterly dividend of $1.64 per ordinary share which will be made payable on 2025-02-14. Ex dividend date: 2025-01-15
• AbbVie's trailing twelve-month (TTM) dividend yield is 3.52%
• AbbVie's payout ratio for the trailing twelve months (TTM) is 212.79%
AbbVie Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2025-01-15 | $1.64 | quarterly | 2025-02-14 |
2024-10-15 | $1.55 | quarterly | 2024-11-15 |
2024-07-15 | $1.55 | quarterly | 2024-08-15 |
2024-04-12 | $1.55 | quarterly | 2024-05-15 |
2024-01-12 | $1.55 | quarterly | 2024-02-15 |
2023-10-12 | $1.48 | quarterly | 2023-11-15 |
2023-07-13 | $1.48 | quarterly | 2023-08-15 |
2023-04-13 | $1.48 | quarterly | 2023-05-15 |
2023-01-12 | $1.48 | quarterly | 2023-02-15 |
2022-10-13 | $1.41 | quarterly | 2022-11-15 |
2022-07-14 | $1.41 | quarterly | 2022-08-15 |
2022-04-13 | $1.41 | quarterly | 2022-05-16 |
2022-01-13 | $1.41 | quarterly | 2022-02-15 |
2021-10-14 | $1.30 | quarterly | 2021-11-15 |
2021-07-14 | $1.30 | quarterly | 2021-08-16 |
2021-04-14 | $1.30 | quarterly | 2021-05-14 |
2021-01-14 | $1.30 | quarterly | 2021-02-16 |
2020-10-14 | $1.18 | quarterly | 2020-11-16 |
2020-07-14 | $1.18 | quarterly | 2020-08-14 |
2020-04-14 | $1.18 | quarterly | 2020-05-15 |
2020-01-14 | $1.18 | quarterly | 2020-02-14 |
2019-10-11 | $1.07 | quarterly | 2019-11-15 |
2019-07-12 | $1.07 | quarterly | 2019-08-15 |
2019-04-12 | $1.07 | quarterly | 2019-05-15 |
2019-01-14 | $1.07 | quarterly | 2019-02-15 |
2018-10-12 | $0.96 | quarterly | 2018-11-15 |
2018-07-12 | $0.96 | quarterly | 2018-08-15 |
2018-04-12 | $0.96 | quarterly | 2018-05-15 |
2018-01-11 | $0.71 | quarterly | 2018-02-15 |
2017-10-12 | $0.64 | quarterly | 2017-11-15 |
2017-07-12 | $0.64 | quarterly | 2017-08-15 |
2017-04-11 | $0.64 | quarterly | 2017-05-15 |
2017-01-11 | $0.64 | quarterly | 2017-02-15 |
2016-10-12 | $0.57 | quarterly | 2016-11-15 |
2016-07-13 | $0.57 | quarterly | 2016-08-15 |
2016-04-13 | $0.57 | quarterly | 2016-05-16 |
2016-01-13 | $0.57 | quarterly | 2016-02-16 |
2015-10-13 | $0.51 | quarterly | 2015-11-16 |
2015-07-13 | $0.51 | quarterly | 2015-08-14 |
2015-04-13 | $0.51 | quarterly | 2015-05-15 |
2015-01-13 | $0.49 | quarterly | 2015-02-13 |
2014-10-10 | $0.42 | quarterly | 2014-11-17 |
2014-07-11 | $0.42 | quarterly | 2014-08-15 |
2014-04-11 | $0.42 | quarterly | 2014-05-15 |
2014-01-13 | $0.40 | quarterly | 2014-02-14 |
AbbVie Dividend per year
AbbVie Dividend growth
AbbVie Dividend Yield
AbbVie current trailing twelve-month (TTM) dividend yield is 3.52%. Interested in purchasing AbbVie stock? Use our calculator to estimate your expected dividend yield:
AbbVie Financial Ratios
AbbVie Dividend FAQ
Other factors to consider when evaluating AbbVie as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy AbbVie stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: AbbVie's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, AbbVie publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, AbbVie distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from AbbVie are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: AbbVie sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, AbbVie distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: AbbVie declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of AbbVie's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review AbbVie's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.